Pro 2013-007 (Announcement of Jianfeng Group on Providing Counter-Guarantees to Corporate Bond Counter-Guarantors)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2013-007
浙江尖峰集团股份有限公司
关于向公司债券反担保人提供反担保的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l本次担保的被担保人(质押权人)名称:天津帝士力投资控股集团有限公司
l本次担保金额:公司拟发行的规模不超过6亿元公司债券的本金及利息
l本次担保是否有反担保:本次对外担保实质是为公司发行公司债进行反担保
l对外担保逾期的累计数量:无
一、担保情况概述
2013年1月22日,公司召开的2013年第一次临时股东大会已批准关于公司发行票面总额不超过6亿元、期限不超过7年的公司债的相关议案,并授权董事会根据市场情况确定本次公司债券是否采用担保及具体担保方式,授权董事会及其授权人士(董事长、董事会秘书)全权办理本次发行公司债券相关事项。详见本公司2013年1月5日披露的《第八届董事会第八次会议决议公告》、《关于发行公司债券方案的公告》和2013年1月23日披露的《2013年第一次临时股东大会决议公告》,上述公告分别披露在《上海证券报》、《中国证券报》和上海证券交易所网站(http://www.sse.com.cn)上。
2013年2月26日,浙江尖峰集团股份有限公司以通信方式召开了第八届第九次董事会,公司现有董事9名,全部出席了本次会议,关联董事蒋晓萌先生、杜自弘先生回避了部分议案的表决,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。经审议与表决,董事会以7票同意、0票反对、0票弃权审议通过了《关于向公司债券反担保人提供反担保的议案》。
为增强本次公司债的偿债保障,降低发行利率,本公司确定由天津天士力集团有限公司(以下简称:天士力集团)为本次公司债提供全额无条件的不可撤销的连带责任保证担保;由天士力集团的大股东天津帝士力投资控股集团有限公司(以下简称:帝士力控股)为天士力集团在该担保责任范围内提供保证方式的反担保。
由本公司将所持有的天士力集团20.76%股权质押给本次公司债券反担保人帝士力控股,作为本公司向帝士力控股在其担保责任范围内提供的反担保。授权公司董事长签署与上述担保及反担保相关的所有法律文件。
本次股权质押的质权人帝士力控股与本公司不存在关联关系;因本公司董事蒋晓萌先生和杜自弘先生也同时担任天士力集团的董事,根据上海证券交易所《股票上市规则》的相关规定,天士力集团是本公司的关联方。
二、被担保人(质押权人)基本情况
1、被担保人(质押权人)名称:天津帝士力投资控股集团有限公司。
2、成立时间: 1998年11月12日。
3、住所:天津北辰科技园区。
4、法定代表人:闫希军。
5、注册资本:3500万元。
6、经营范围:技术开发、咨询、服务、转让生物技术及产品,以自有资金对保健食品、高科技行业进行投资。
7、与本公司关系:帝士力控股为本公司联营公司天士力集团的第一大股东,与本公司不存在关联关系。
8、财务情况:
按经审计的合并财务报表口径,截至2011年末,帝士力控股资产总额1,110,405.48万元,负债总额683,441.77万元,所有者权益合计(含少数股东权益)426,963.71万元。2011年度,实现营业收入978,075.32万元,净利润(含少数股东权益)31,842.31万元。
按未经审计的合并财务报表口径,截至2012年三季度末,帝士力控股资产总额1,135,037.33万元,负债总额663,027.71万元,所有者权益合计(含少数股东权益)472,009.62万元;2012年1-9月,实现营业收入730,728.46万元,净利润(含少数股东权益)56,912.14万元。
三、股权质押反担保的主要内容
(一)股权质押反担保内容
天士力集团为本公司拟发行的票面总额不超过6亿元、期限不超过7年的公司债提供全额无条件不可撤消的连带责任保证担保。由帝士力控股为天士力集团在该担保责任范围内提供保证方式的反担保。
本公司将所持有的天士力集团20.76%股权质押给帝士力控股,作为本公司向帝士力控股在其担保责任范围内提供的反担保。
(二)用于设定质押的反担保资产情况
公司本次用于反担保的质押资产是所持有的天士力集团20.76%股权,截止2011年末,该部分股权的投资成本为5,067.34万元。
1、天士力集团成立于2000年3月30日,注册地址:天津北辰科技园区,现有注册资本:23,784.38万元,其中:帝士力控股占61.68%、本公司占20.76%。经营范围:对外投资、控股;天然植物药种植及相关加工、分离;组织所属企业开展产品的生产、科研、销售、进出口经营业务;各类商品、物资的批发、零售;技术开发、咨询、服务、转让生物技术(不含药品生产与销售)及产品等。天士力集团是以大健康产业为主线,以制药业为中心,集生产、投资于一体的多元化集团企业。截止2012年9月末,天士力集团持有上市公司天士力制药集团股份有限公司47.27%的股权。
2、用于设定质押的反担保资产账面价值:截至2011年12月31日,反担保资产经审计的长期股权投资帐面价值35,239.73万元。截至2012年9月30日,反担保资产未经审计的长期股权投资帐面价值46,012.89万元。
3、用于设定质押的反担保资产在用于本次质押前不存在质押或者其他第三人权利、不涉及诉讼、仲裁事项,不存在查封、冻结等司法措施等情形以及妨碍权属转移的其他情况。
4、天士力集团2011年度财务报告经具从事证券、期货业务资格的天健会计师事务所(特殊普通合伙)审计,并出具标准无保留意见的审计报告。截至2011年12月31日,天士力集团经审计的合并口径资产总额1,041,815.88万元,负债总额634,383.72万元,归属于母公司所有者权益合计169,366.60万元。2011年度,实现主营业务收入927,977.29万元,利润总额86,209.96万元,归属于母公司所有者的净利润24,656.61万元。
截至2012年9月末,天士力集团未经审计的合并口径资产总额1,090,843.81万元,负债总额612,510.59万元,归属于母公司所有者权益合计221,974.93万元。2012年1-9月,实现主营业务收入694,726.89万元,利润总额104,716.12万元,归属于母公司所有者的净利润56,550.32万元。
四、董事会意见
1、股权质押反担保的必要性
由天士力集团为本次公司债券提供担保能切实增强公司债的偿债保障,有利于降低债券发行成本。帝士力控股向天士力集团提供保证方式的反担保,同时本公司对帝士力控股提供股权质押方式的反担保,是本次公司债券担保方案的组成部分,已经2013年第一次临时股东大会决议授权。上述反担保措施符合本公司及股东的整体利益。
2、股权质押反担保风险
由帝士力控股向天士力集团提供保证方式的反担保, 本公司向帝士力控股提供股权质押方式的反担保,实质是为本公司自身的融资进行担保。只要本公司能够按期偿还公司债券的本息,本次股权质押反担保的风险很小,不会影响公司经营。
五、累计对外担保数量及逾期担保的数量
截止本公告披露日,公司及其控股子公司已批准的对外担保总额为7,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的4.93%;公司对控股子公司已批准的担保总额为73,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的51.40%。
截止本公告披露日,公司及其控股子公司对外担保实际余额为7,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的4.93%;公司对控股子公司的担保实际余额为18,481.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的13.01%。
截止本公告披露日,本公司没有逾期担保。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一三年二月二十六日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31